Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Stomach Neoplasms 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Ovarian Neoplasms 1 Endometrial Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Ovarian Epithelial 1 Adenocarcinoma of Lung 1 Adenocarcinoma 1

Interventions

Oxaliplatin 19 pembrolizumab 13 Fluorouracil 12 Leucovorin 11 Capecitabine 11 Paclitaxel 10 Gemcitabine 8 Docetaxel 8 zolbetuximab 6 cemiplimab 6 Cisplatin 6 Albumin-Bound Paclitaxel 6 durvalumab 5 Ramucirumab 5 Radiotherapy 5 Irinotecan 4 Cyclophosphamide 4 130-nm albumin-bound paclitaxel 4 trastuzumab deruxtecan 3 tislelizumab 3 lenvatinib 3 enzalutamide 3 darolutamide 3 Trastuzumab 3 Taxes 3 S 1 (combination) 3 Radiosurgery 3 Pemetrexed 3 Nivolumab 3 Carboplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × bemarituzumab × 1 year × Clear all

NCT06967987 2026-01-21

BEMAFLOT

Institut Cancerologie de l'Ouest

Phase 2 Withdrawn

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡